featured
PCSK9 Inhibition With Orally Administered NNC0385-0434 in Patients With Hypercholesterolaemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial
Lancet Diabetes Endocrinol 2024 Feb 01;[EPub Ahead of Print], MJ Koren, O Descamps, Y Hata, EM Hengeveld, GK Hovingh, I Ikonomidis, MD Radu Juul Jensen, IH Langbakke, FMAC Martens, AL Søndergaard, A Witkowski, W KoenigFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.